
In this episode of Denatured, you’ll hear Philip Jacob Rosenfeld, professor of Ophthalmology at the University of Miami Health System and Bascom Palmer Eye Institute, and Wesley Jackson, chief science officer at Valitor. We talk about the eye condition call wet age-related macular degeneration (AMD), the limits of anti‑VEGF therapy and the push for true durability to change a patient’s life.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsPhilip Jacob Rosenfeld, Professor of Ophthalmology, University of Miami Health System, Bascom Palmer Eye InstituteWesley Jackson, Chief Science Officer, Valitor Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival

The supply chain fault lines of modern pharma

Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease

Breaking borders: Building biotech scale in Benelux
Free AI-powered recaps of BioSpace and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.